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Abstract 
Our study aimed to evaluate changes in the epidemiology of pathogens causing surgical site infections 
(SSIs) in England between 2000 and 2013 in the context of intensified national interventions to reduce 
healthcare-associated infections introduced since 2006. National prospective surveillance data on 
target surgical procedures were used for this study. Data on causative organism were available for 
72% of inpatient-detected SSIs meeting the standard case definitions for superficial, deep and organ-
space infections, (9,767/13,531) which were analysed for trends. A multivariable logistic linear mixed 
model with hospital random effects was fitted to evaluate trends by pathogen. S. aureus was the 
predominant cause of SSI between 2000 (41%) and 2009 (24%), decreasing from 2006 onwards 
reaching 16% in 2013. Data for 2005-2013 showed that the odds of SSI caused by S. aureus decreased 
significantly by 14% per year (aOR: 0.86; 95% CI: 0.83-0.89) driven by significant decreases in 
MRSA (aOR: 0.71; 95% CI: 0.68-0.75). However a small significant increase in methicillin-sensitive 
S. aureus was identified (aOR: 1.06; 95% CI: 1.02–1.10). Enterobacteriaceae were stable during 2000-
2007 (12% of cases overall), increasing from 2008 (18%) onwards, being present in 25% of cases in 
2013; the model supported these increasing trends during 2007-2013 (aOR: 1.12; 95% CI: 1.07-1.18). 
The decreasing trends in S. aureus SSIs from 2006 and the increases in Enterobacteriaceae SSIs from 
2008 may be related to intensified national efforts targeted at reducing MRSA bacteraemia combined 
with changes in antibiotic use aimed at controlling C. difficile infections.  
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Introduction  
 
Surgical site infections (SSIs) are the third most common healthcare-associated infections (HCAIs) 
and are associated with excess length of stay, hospital costs and mortality [1-3]. The  national SSI 
surveillance system in England operated by Public Health England (PHE)  has captured data on micro-
organisms reported as causing SSI since 1997, but evidence for trends in aetiology as observed in 
bacteraemias captured separately by PHE have not been comprehensively assessed [4-6]. 
  
Data captured by PHE’s voluntary surveillance of laboratory isolates in England and Wales showed 
that bacteraemia due to methicillin-resistant S. aureus (MRSA) increased sharply from 1990 to 2003 
[7]. Progress in the control of HCAIs was subject to scrutiny by England’s National Audit Office in 
2004 and the Public Accounts Committee in 2005 highlighting problems with commitment to hospital 
hygiene. In October 2005 the Department of Health (DoH) expanded an existing policy of mandatory 
public reporting of MRSA bacteraemia counts (since 2001) by introducing enhanced (patient-level) 
surveillance. The DoH also introduced targeted infection control policies to standardise and improve 
practices around the prevention of MRSA which included MRSA screening and decolonisation, care 
of invasive devices and hand hygiene [5;7;8]. 
 
In addition, all NHS hospitals were required to achieve the target of reducing their rate of MRSA 
bacteraemia by 50% by 2008 (from a 2004 baseline), supported by visits to hospitals by national 
improvement teams (from 2008). Considerable reductions in rates of MRSA bacteraemia were noted 
since 2006 [5;7;9].  
 
Concern about C. difficile infection (CDI) led to additional initiatives including mandatory public 
reporting (introduced in 2004), reduction targets for all NHS hospitals and antimicrobial prescribing 
guidance introduced in 2007 [10;11]. This guidance recommended the restricted use of broad-
spectrum antimicrobials particularly quinolones and cephalosporins. Considerable reductions in CDI 
cases occurred from 2008 [9;12;13]. 
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The emergence of E.coli infections has also caused concern. Using PHE’s voluntary laboratory 
surveillance data, E. coli reported as causing bacteraemia in England increased by 33% between 2004 
and 2008 [6].  
 
For this study, SSI micro-organism data captured by PHE’s national SSI surveillance provided an 
opportunity to ascertain whether similar trends to those observed in bacteraemia were also present in 
SSIs.  
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Materials and methods  
 
Case ascertainment and data collection process  
 
The data for this study were captured by the national SSI surveillance system (SSISS). This 
programme was established in 1997 by the Public Health Laboratory Service, now PHE to provide a 
benchmarking service and to enable hospitals to use data to improve practice. Initially participation 
was voluntary but since 2004, all NHS hospitals have been mandated to undertake a minimum of three 
months surveillance each year in orthopaedic surgery. An additional 13 categories of surgical 
procedure are offered for voluntary national surveillance [14;15]. Thus the surveillance dataset 
comprises orthopaedic surgical procedures collected annually by most hospitals and other surgical 
categories collected on an intermittent basis by some hospitals. All participating hospitals are trained 
by PHE in using the standard case definitions for superficial, deep or organ-space SSIs based on 
internationally recognised criteria with minor modifications in the English protocol [15]. In England 
the presence of pus cells is additionally required for microbiological confirmation and for superficial 
SSIs, a clinician diagnosis must accompany two clinical signs and symptoms. All eligible patients are 
followed up on a prospective basis to identify SSIs within 30 days of surgery for superficial SSIs or 
non-implant procedures. For procedures with an implant, an SSI can be reported for up to one year. 
Data validation is undertaken to correct errors and from 2004 has been handled automatically via the 
web-based application. Participating hospitals can voluntarily report up to three clinically significant 
isolates using a standard set of codes denoting species, genus, or a generic group e.g. ‘coliforms’. 
Antimicrobial susceptibility data are collected for S. aureus. S. aureus can be reported as methicillin-
sensitive, methicillin-resistant or vancomycin-intermediate (VISA). Methicillin-resistant S,aureus is 
inclusive of VISA. Data on surgical antimicrobial prophylaxis agents are not collected. 
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Inclusion criteria  
 
Data on causative organism from SSI cases detected during the inpatient stay between 1 January 2000 
and 31 December 2013 were included. Data from non-NHS hospitals were excluded. The data covered 
13 defined surgical categories. SSIs diagnosed on readmission were excluded as readmission 
surveillance did not become mandatory until 2008. Given the nature of our study (examining 
long-term trends in the microbial aetiology of SSIs), we wanted to exclude a potential source 
bias deriving from the mandatory readmission surveillance introduced part way through our 
study period. 
 
Statistical analysis 
 
This study was based on an analysis of cases of SSI. All pathogens reported as a causative organisms 
were included in the analysis.  For analyses at genus or family level, monomicrobial and 
polymicrobial cases were combined provided the latter included species from the same genera or 
family.  
 
Fixed and mixed effects models were fitted using Stata/SE 13.1 (StataCorp, TX). Standard logistic 
regression was used to analyse binary outcome data under a Bernoulli distribution. The mean annual 
change in the odds of SSI due to a pathogen was estimated using a linear predictor with seven 
confounding variables: age (continuous), patient sex, ASA score (pre-operative health status 
dichotomised into <3 and ≥3), wound class (dichotomised into clean/clean-contaminated and 
contaminated/dirty), duration of operation (dichotomised according to the 75th percentile value 
rounded to the nearest hour), days of in-patient follow-up (continuous) and surgical category. For the 
surgical category predictor data from eight surgical categories were compressed into four groups to 
permit model maximisation: gastro-intestinal (large, small bowel and gastric), orthopaedic (total hip 
and knee prosthesis, hip hemiarthroplasty and reduction of long bone fracture), coronary artery bypass 
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graft (CABG) and vascular surgery. The other five categories were excluded from the model because 
the annual volumes were small and they were unrelated to the four groups. As our dataset comprised 
inpatient-detected cases, we adjusted for variation in the length of follow-up during the inpatient stay. 
The logistic linear mixed model added random hospital effects to take into account extra variation not 
explained by the confounding factors. The information criterion approach (AIC) was used to 
determine the relative optimum fit compared to the fixed effects model. Adjusted ORs, 95% CIs and 
p-values are reported. 
 
The time periods 2000-2005 and 2005-2013 were selected for modelling S. aureus SSI trends to 
represent pre and post-implementation of national guidelines on the prevention and control of HCAIs, 
particularly MRSA, introduced from 2006. The periods 2000-2007 and 2007-2013 were used for 
modelling trends in Enterobacteriaceae SSIs as these periods represented pre and post-implementation 
of the antimicrobial prescribing guideline introduced in 2007. Enterobacteriaceae merited focus given 
the recent emergence of antimicrobial resistance among Gram-negative bacilli. Each post-
implementation period included the year preceding the national policies of interest.   
 
Changes in microbial aetiology were modelled by surgical category based on the same nine modules 
included in the surgical category predictor in the main analysis. The analysis by surgical category was 
based on ≥100 cases with organism data per pooled period: 2000-2005 (baseline prior to national 
HCAI policies) and 2008-2013 post-implementation of HCAI policies).  
Separate analyses deep incisional or organ/space for SSIs were undertaken to determine if similar 
effects were observed in this clinically important sub-group. This analysis included CoNS as their 
presence in these more severe SSI is not likely to reflect colonisation.  
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Results  
 
Between 2000 and 2013, patient-level data on 968,662 procedures and 13,531 in-hospital SSIs were 
submitted by 253 acute NHS hospitals in England (Table 1). Orthopaedic procedures accounted for 
84% of total volume, followed by CABG (7%) then gastro-intestinal surgery (4%). The number of 
procedures included in the surveillance increased steadily from April 2004 (not shown), reflecting the 
introduction of the mandatory surveillance of SSI in orthopaedic surgery.  
 
The proportion of SSIs that were deep/organ-space varied by surgical category. Complex SSIs were 
more likely to be captured in procedures with a longer post-operative hospital spell. The crude SSI 
incidence was highest in gastro-intestinal surgery and lowest in prosthesis surgery (Table 1). 
 
Data on causative micro-organism was reported for 72% of SSIs (9,767/13,531), although this 
proportion declined gradually from 82% in 2000 to 58% in 2013 (Table 2). Of 9,767 SSIs, 29% 
(n=2,838) were polymicrobial comprising 6,419 isolates. S. aureus accounted for 33% of SSIs 
(3,250/9,767) inclusive of SSI cases where both MRSA and MSSA were isolated in the same patient 
(n=20). Enterobacteriaceae accounted for 16% of SSIs (1,536/9,767) of which 8% (149/1,536) 
comprised solely Enterobacteriaceae organisms isolated in the same patient. Overall, the majority of 
Enterobacteriaceae were reported as ‘coliforms’; 47% (654/1,387) and 52% (70/149) in the 
monomicrobial and polymicrobial subsets respectively. Due to the reporting of ‘coliforms’, data on 
Enterobacteriaceae species were aggregated to family level for analysis.  
 
S. aureus was the predominant pathogen between 2000 and 2009, peaking at 45% of SSI cases in 2002 
(Table 2, Figure 1). This predominance persisted despite an initial decline in 2006 and steep decreases 
from 2007 (38%) to 2009 (24%). By 2013, S. aureus accounted for 16% of SSIs. This trend was 
explained by marked reductions in MRSA from 2006. Enterobacteriaceae were the second most 
frequent pathogens accounting for 12% of SSIs overall during 2000-2007 (inter-year range, 9% - 14%) 
increasing to 18% of cases in 2008. They overtook S. aureus in 2010 (22%) increasing to 25% in 
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2013. Similar trends were observed by surgical category (Figure 1). Similar trends in S. aureus and 
Enterbacteriaceae were observed among deep-organ-space SSIs (Table 2).  
 
Multi-variable analysis 
 
For the analysis of trends in aetiology among cases of SSI, a total of 7,476 inpatient SSIs with 
microbiology data were available for the multivariable analysis based on eight surgical categories. The 
excluded SSIs (2,291/9,767) were due to the four surgical categories that could not be grouped with 
any of the nine categories and missing data on required covariates. The majority of the missing data 
related to ASA score (1,480/2,291).  
 
After controlling for covariates, there was insufficient evidence to support an association between S. 
aureus and time (year) during 2000-2005 (Table 3). A similar conclusion applied to MRSA and 
Enterobacteriaceae SSIs. These reflected the unchanging variation in the underlying data. A barely 
detectable decline in the odds of MSSA was found in this period (aOR: 0.94; 95% CI: 0.88 – 1.01; 
p=0.078). 
 
The decreases in S. aureus as a relative cause of SSI during 2005-2013 were strongly supported by the 
model. The adjusted odds of SSI due to S. aureus was 0.86 per unit increase in time (year) (95% CI: 
0.83 – 0.89). This trend was due to significant decreases in MRSA (aOR: 0.71; 95% CI: 0.68 - 0.75). 
A small but significant relative increase in MSSA occurred during this time (aOR: 1.06; 95% CI: 1.02 
– 1.10).  
 
During 2000-2007, the model showed no evidence of change in the contribution of Enterobacteriaceae 
as reported causes of SSI, reflecting the crude trends. However, during 2007-2013, the observed 
increase in SSIs due to Enterobacteriaceae were strongly supported by the model; the estimated 
adjusted odds ratio was 1.12 per unit change in time (year) (95% CI: 1.07 – 1.18). 
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Trends in the subset of deep-organ-space SSIs were similar to those observed in main analyses except 
for MSSA during 2005-2013 (Table 3) where the positive association between MSSA and time 
disappeared although this could be due to the effect of a reduced sample size. The increasing trend in 
CoNS 2005-2013 missed statistical significance (aOR: 1.07; 95% 1.00 – 1.14; p=0.065).    
 
There was a significant variation between hospitals for all analyses were based on all SSIs. For 
example, in the analysis for MRSA during 2005-2013, the estimated variance between hospitals was 
0.63 (SE: 0.08) and in the analysis for Enterbacteriaceae during 2007-2013, this was 0.58 (SE: 0.08).  
However, the effect of hospital difference was minimal in terms of model fit for some of the 
deep/organ-space pathogens except in 2005-2013 and 2007-2013 where the mixed model was a 
significant improvement over the logistic model for all pathogens examined.   
 
The unadjusted analysis yielded similar results in terms of the direction of effect as the adjusted 
analysis except for MSSA and CoNS (data not shown). For MSSA, the annual decrease was much 
more distant from the null in 2000-2005, and in 2005-2013 the annual increase was strongly non-
significant. For deep/organ-space SSIs, the unadjusted increase in CoNs was significant in 2000-2005 
(p=0.022) and in 2005-2013 (p=0.030).  
 
For the multivariable analysis by surgical category, two pooled time periods were used; 2008-2013 
compared to 2000-2005 (baseline). Of 8,395 SSI cases with micro-organism data for the two 
combined periods, 23% (n=1,898) were excluded as described earlier leaving 6,497 cases available for 
analysis. The majority of missing records were due to missing ASA score data (1,212/1,898). Changes 
in microbial aetiology in gastric surgery were not evaluated due to sparse data (<25 SSI cases per time 
period). The adjusted odds of SSIs due to MRSA decreased significantly between these two periods in 
all eight categories examined with the largest decrease observed in CABG surgery (Table 4). The 
adjusted odds of Enterobacteriaceae increased significantly in all categories except in CABG and knee 
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prosthesis surgery, where no evidence of change was identified. The largest increases were in open 
reduction of long bone fracture and large bowel surgery. The odds of SSI due to CoNS (not shown) 
increased significantly in hip prosthesis (aOR: 1.62; 95% CI: 1.10 – 2.40; p=0.016), knee prosthesis 
(aOR: 2.22; 95% CI: 1.43 – 3.44; p<0.001), hip hemiartroplasty (aOR: 3.85; 95%CI: 2.07 – 7.15; 
p<0.001) and CABG surgery (aOR: 2.63; 95% CI: 1.64 – 4.22; p<0.001). The unadjusted analysis 
yielded similar results in terms of direction of effect and significance except for CoNS in hip 
prosthesis as this showed a non-significant increase (data not shown).  
 
We also examined the background trends in the odds of all-cause SSI based on all exposure data for 
each of the eight surgical categories also using the mixed model (not shown). The data comprised 
810,763 procedures and 10,350 in-hospital SSIs. All covariates were included except surgical 
category. The adjusted annual odds of in-hospital SSI decreased significantly in each category except 
in large bowel surgery where the odds increased significantly 2% annually over the study period (95% 
CIs: 1.01 – 1.03). 
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Discussion  
 
Using 14 years of national surveillance data, this study identifies for the first time important changes 
in the microbial aetiology of SSIs in English NHS hospitals. A significant decrease in S. aureus was 
identified with a subsequent significant rise in Enterobacteriaceae. Despite a background of decreasing 
odds in all-cause SSI at surgical category level, this masked changes in the underlying microbial 
aetiology. The subgroup of deep-organ space SSIs exhibited similar trends. The multivariable analysis 
showed that our results were not explained by case-mix, surgical category, variation between hospitals 
or length of hospital stay.  
 
We postulate that the changing trends in SSI aetiology coincided temporally with a series of national 
HCAI policies introduced in England since 2006. Given the ecological nature of this analysis, it is not 
possible to disentangle the impact of each specific intervention. However, the multi-modal strategy 
involving vertical (targeting a single pathogen) and horizontal (broad-based) activities may have had a 
cumulative impact on the trends in pathogens causing SSI that we have identified. 
 
The national MRSA screening and decolonisation strategy, introduced in England in November 2006, 
was targeted at elective patients in high risk specialties [8]. This was expanded in July 2008 to cover 
all NHS elective (by March 2009) and emergency admissions (by December 2010) [8;16;17]. Despite 
the initial targeted screening strategy, our study identified moderate decreases in MRSA as an 
aetiological cause of SSI in 2006 and 2007. The steep decreases in 2008 and in subsequent years 
appeared to coincide with the expanded screening policy. However a prevalence study in 2011 found 
that 61% of emergency and 81% of elective admissions in NHS Trusts used universal screening [18]. 
If uptake of universal screening was low from the start, this suggests other drivers may have 
influenced the marked reduction MRSA SSIs in 2007 and 2008. Our study also identified significant 
reductions in MRSA SSIs in all eight surgical categories examined. The MRSA SSIs trends were 
similar to those observed for MRSA bacteraemia, captured separately by the English mandatory 
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programme where moderate decreases from 2004 to 2006 occurred declining steeply from 2007 [7]. 
This marked decrease coincided with the national guidance on infection prevention for a range of 
clinical procedures. The national 50% reduction target for MRSA bacteraemia was achieved by 2008. 
 
The effects of antimicrobial prescribing guidance introduced in August 2007 aimed at controlling 
CDIs may have also indirectly contributed to the steep MRSA reductions. Exposure to broad-spectrum 
antimicrobials, particularly cephalosporins and quinolones has been shown to be a risk factor for the 
acquisition of MRSA [19-22]. Restricting the use of these antibiotic classes would be expected to 
reduce the selection pressure on MRSA. Thus a collective effort across NHS Trusts in reducing the 
use of several broad-spectrum antibiotics aimed at reducing the burden of CDIs may have had a 
favourable ecological impact on MRSA. The impact of restricted cephalosporin use on the decreases 
in MRSA and CDIs has been reported in single-centre studies [23;24]. 
 
The decreasing prevalence of EMRSA-16, one of two dominant MRSA epidemic strains is of interest 
although these predate the national MRSA control measures [25].The changing ecology of this strain 
however may have also had some influence in the reduction of MRSA SSIs and mandatory MRSA 
bacteraemia cases captured by PHE. 
 
The increase in deep/organ-space SSI caused by CoNS between 2005 and 2013, although in this 
analysis missed statistical significance, was based on a small sample. CoNS are however indolent 
pathogens and infections frequently present too late to be captured by inpatient-based surveillance so 
are likely to be under-reported, hence the small sample size. It should be noted that our analysis by 
surgical category, though based on all SSI types indicated an increase in CoNS in orthopaedic and 
CABG surgery both of which include prosthetic material. Potential explanations for the increase 
include emerging resistance to agents used for prophylaxis such as glycopeptides and aminoglycosides 
both of which are used as surgical prophylaxis in orthopaedic surgery in some NHS Trusts [26-28] or 
sub-optimal skin decontamination due to reduced susceptibility of staphylococci to chlorhexidine [29]. 
In the UK, there is, as yet, no specific evidence of any reduced susceptibility to chlorhexidine. 
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An earlier study based on PHE’s voluntary laboratory-based surveillance data indicated that 
bacteraemia episodes due to E. coli and Klebsiella spp. increased by 33% and 14% respectively from 
2004 to 2008 [6]. This is an important context for the SSI aetiology trends we observed in our study.  
 
The steep decrease in MRSA in 2008 and 2009 we identified were concurrent with steep increases in 
Enterobacteriaceae as a cause of SSI. A compensatory replacement may be argued although MSSA 
would have perhaps been a more likely organism for this effect. Nevertheless the marked increase 
observed for Enterobacteriaceae coincided temporally with the new antimicrobial prescribing guidance 
introduced in 2007 to address the emerging problem of CDI. This guidance focused on reducing the 
use of broad-spectrum agents, in particular cephalosporins and fluoroquinolones. The CDI reduction 
target and associated financial penalties, both introduced in 2007, would have compelled hospitals to 
adopt the new prescribing guidance thus initiating changes in hospital formulary. Prominent decreases 
in CDI cases occurred in 2008 and in subsequent years [13]. Indeed substantial reductions in the use of 
fluoroquinolones, second and third-generation cephalosporins from 2005 to 2009 in English NHS 
hospitals were observed (>40%, >50% and >22% respectively), whilst the use of carbapenems and 
combination beta-lactamase inhibitors increased [30].. Consumption of the quinolone and 
cephalosporin classes in England is currently the lowest in the European Union [31]. 
 
Thus, one explanation for the increase in Enterobacteriaceae as a cause of SSI is this antimicrobial 
stewardship-based (horizontal) approach to reducing CDIs. The impact of the antimicrobial 
prescribing guidance extended beyond CDIs, changing the antibiotics used for surgical prophylaxis 
and potentially increasing the opportunity for Enterobacteriaceae to cause SSI. Amended hospital 
formularies may include agents with less favourable pharmacokinetic properties or narrower 
antimicrobial spectra, increasing the risk of Gram-negative SSIs. Aminoglycosides or β-lactam/β-
lactam inhibitor combinations are the new mainstay for Gram-negative cover. However it is possible 
that the existing surgical antimicrobial prophylaxis regimens are not always achieving above-MIC 
levels at the surgical site. Conditions of physiological stress such as significant blood loss and fluid 
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replacement may further decrease tissue concentrations [32;33]. Potentially lower levels might also 
occur in obese patients [34] than for agents used in the earlier part of our study period. In addition, 
antibiotic-resistant Enterobacteriaceae may be refractory to the effects of some of the current 
prophylaxis regimens [35] due to the emergence of extended-spectrum β-lactamases and 
carbapenamase-producing Enterobacteriaceae reported internationally [36;37]. As we did not capture 
antibiotic susceptibility data on Gram-negative SSIs, we could not determine how much of the 
increase in Enterobacteriaceae SSIs was fuelled by antibiotic resistance.  
 
Our study identified increases in SSIs due to Enterobacteriaceae affecting six of eight surgical 
categories in a range of clean and clean-contaminated procedures. The largest effects were observed in 
open reduction of long bone fracture and large bowel surgery. No evidence of an increasing trend was 
found for knee prosthesis perhaps due to small sample sizes or for CABG surgery which may be due 
to lower limb donor site SSIs being seeded post-operatively by patient flora therefore less influenced 
by changes in antibiotic prophylaxis. The increase in SSs in bowel surgery with enteric organisms 
does raises concerns that inadequate prophylaxis may be the main driver here. 
 
Trends in the microbial aetiology of SSIs reported internationally show similarities with the English 
results. For example, a significant decrease in MRSA SSIs and a significant increase in SSIs due to 
ceftriaxone-resistant E. coli have been reported in Australia between 2002 and 2013 based on data 
from hospitals in Victoria state [38]. Data from the USA derived from two separate summaries for 
2006/07 and 2009/10 showed that S. aureus remained stable at 30% of SSI isolates in both periods 
although MRSA decreased from 49% to 44% respectively. Although the proportion of SSI isolates due 
to E.coli or K. pneumoniae/K. oxytoca remained unchanged, an increase in cephalosporin-resistance 
was noted among E. coli isolates from 5% to 11% over these two periods [39;40]. Data from sentinel 
laboratories in the USA participating in CDC’s bacterial surveillance network also showed reductions 
in MRSA; the modelled incidence of hospital-onset invasive MRSA significantly decreased 9.4% 
annually from 2005 to 2008. The authors believed this reflected the dissemination of MRSA 
16 
 
prevention practices in US hospitals [41]. However, as of 2011, CDIs remain high in the USA as well 
as the use of broad-spectrum antibiotics in acute hospitals [42;43].    
 
In England the decrease in MRSA as a reported cause of SSI may reflect the success of intensified 
MRSA control strategies and the impact of changes in antimicrobial prescribing, the latter reducing 
the propensity for MRSA selection. The increase in Enterobacteriaceae as reported causes of SSI 
however demands further study given the increasing antimicrobial resistance among these pathogens 
and the need to inform the selection of appropriate and effective antimicrobial prophylaxis.  
 
Limitations  
 
Since neither patient nor hospital-level data on hospital infection control interventions or surgical 
prophylaxis are collected, an inference is made between the timing of large-scale national policies and 
the trends in reported SSI pathogens Although ecological analyses are useful at population-level it is 
not possible to establish direct cause and effect.  
 
An analysis of trends in the leading species of Enterobacteriaceae (E. coli and K. pneumonia) could 
not be undertaken due to the high proportion of organisms reported as “coliforms”.  
 
Although there was a gradual decline in the proportion of SSIs with causative organism data reported, 
there was no temporal relationship between tis decline and the observed microbial aetiology trends.  
 
Some of the organisms reported for superficial SSIs and included in the main analysis may represent 
colonisation with regional flora. However, similar trends in aetiology were observed for deep/organ-
space SSIs where such contamination is much less likely.  
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Participation in the non-orthopaedic categories is voluntary resulting in lower hospital coverage 
compared to the mandatory orthopaedic categories, intermittent or no surveillance in any given year. 
. 
Conclusion  
 
S. aureus reported as causing SSIs decreased significantly in England during 2005-2013 and was 
attributable to significant decreases in MRSA SSIs. These trends coincided with intensified efforts to 
control MRSA in acute NHS hospitals particularly the screening and decolonisation of MRSA carriers. 
The impact of the national antimicrobial prescribing guidance directed at reducing CDIs may have 
also contributed to these trends. A small but significant increase in MSSA occurred concurrently. 
 
Enterobacteriaceae reported as causing SSIs increased significantly after 2007, an effect that was 
present across the majority of surgical categories studied. This trend may be temporally linked with 
the national antimicrobial guidance. Changes to hospital formulary to control CDIs may have led to 
the selection of surgical antibiotic prophylaxis with a reduced spectrum of cover against Gram-
negative bacilli either due to the effects of antibiotic resistance or inadequate tissue concentrations of 
prophylaxis at the surgical site. 
 
Our study identified important changes in the aetiology of SSI in England and we postulate that 
interventions targeted at one HCAI may have indirect consequences for other HCAIs. The true impact 
of antimicrobial stewardship programmes needs to be evaluated in terms of benefits and harms [44]. 
Further study is needed to better understand these effects and to ensure that antimicrobial surgical 
prophylaxis is optimised.  
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Fig 1: Trends in key pathogens reported as causes of in-hospital SSIs for selected surgical 
categories, NHS hospitals, England
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Table 1: Number of surgical procedures and in-hospital surgical site infection (SSI) cases by surgical category, data from 2000 to 2013, NHS 
hospitals, England 
 
 
 
 
 No. 
participating 
hospitals 
 In-hospital SSI cases Cumulative 
Incidence 
Type of procedure                       No. procedures 
(%) 
Median length of 
hospital stay (days) 
Total Superficial* 
No. (% of SSI) 
Deep/organ-space* 
No. (% of SSI) 
% 95% CI 
Abdominal hysterectomy 15,150 (1.6%) 68 4 181 148 (81.7%) 33 (18.2%) 1.2% 1.0% – 1.4% 
Bile duct/liver/pancreatic surgery 3,214 (0.3%) 12 9 196 109 (55.6%) 87 (44.1%) 6.1% 5.3% - 7.0% 
Cholecystectomy 1,162 (0.1%) 14 6 43 11 (25.6%) 32 (74.4%) 3.7% 2.7% - 5.0% 
Coronary artery bypass graft 63,065 (6.5%) 30 7 2,156 1,414 (65.6%) 741 (34.4%) 3.4% 3.3% - 3.6% 
Gastric surgery 1,818 (0.2%) 16 10 74 23 (31.5%) 50 (68.5%) 4.1% 3.2% - 5.1% 
Hip hemiarthroplasty 85,511 (8.8%) 183 13 2,072 1,280 (62.0%) 783 (38.0%) 2.4% 2.3% - 2.5% 
Hip prosthesis 329,688 (34.0%) 235 5 2,144 1,472 (68.8%) 666 (31.2%) 0.7% 0.6% - 0.7% 
Knee prosthesis 336,836 (34.7%) 226 5 1,150 824 (71.9%) 322 (28.1%) 0.3% 0.3% - 0.4% 
Large bowel surgery 34,777 (3.6%) 93 9 3,118 1,917 (61.6%) 1,197 (38.4%) 9.0% 8.7% - 9.3% 
Limb amputation 5,907 (0.6%) 55 14 424 316 (74.7%) 107 (25.3%) 7.2% 6.5% - 7.9% 
Open reduction of long bone fracture 65,279 (6.7%) 139 10 797 586 (73.5%) 211 (26.5%) 1.2% 1.1% - 1.3% 
Small bowel surgery 6,941 (0.7%) 34 9 517 342 (66.7%) 171 (33.3 %) 7.5% 6.8% - 8.1% 
Vascular surgery 19,314 (2.0%) 60 7 659 496 (75.7%) 159 (24.3%) 3.4% 3.2% - 3.7% 
Total 968,662 253 - 13,531 8,938 4,559 - 
CI, Confidence Interval; *based on SSI cases with SSI type data given 
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Table 2: Distribution of organisms reported to cause in-hospital SSI cases, NHS hospitals, England, 2000 to 2013  
 
*includes ‘coliforms’; †methicillin-resistant S. aureus; ‡ methicillin-sensitive S. aureus; § coagulase-negative staphylococci; || other organisms or Gram-positive and Gram-negative combinations  
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
A
ll
 S
S
Is
 
Enterobacteriaceae* 
10.8% 9.4% 11.8%  12.3% 13.1% 9.9% 13.7%  12.2% 18.0% 23.1%  22.2%  23.1% 23.1%  24.6% 
MRSA†  25.4% 27.8% 30.8% 25.9% 25.6% 29.0% 24.8% 23.7% 15.4% 9.1% 5.9% 4.1% 4.5% 4.4% 
MSSA‡  15.3% 12.6% 13.9% 13.5% 13.0% 12.4% 14.5% 14.4%  15.4% 14.9% 14.2% 13.3% 15.1% 12.0% 
S. aureus  40.9% 40.6% 44.6% 39.8% 39.0% 41.7% 39.8% 38.0% 30.8% 24.2%  20.2% 17.4% 19.6%  16.4% 
CoNS§ 3.7% 5.5%  8.0% 6.6% 8.3% 6.0% 7.1% 8.3%  10.7% 10.4% 10.6% 9.6% 9.1% 12.4% 
Pseudomonas spp.  6.5% 5.0% 5.5% 5.7% 4.3%  5.1%  5.5% 5.4% 6.2% 6.1% 4.6%  5.4%  6.5% 4.7% 
Enterococcus spp. 2.7% 3.3% 2.4% 4.8% 3.6%  4.6% 3.6% 3.9% 4.7%  2.5% 4.0%  4.7% 5.8%  4.2% 
Other|| 35.7% 36.4% 27.7% 31.1% 32.1% 33.2% 30.8%  32.1%  29.7%  33.9% 38.6% 40.0% 36.0% 37.8% 
SSIs with microbiology data 678 818 780 771 816 769 759 613 657 637 677 615 603 574 
Total SSI cases 825 976 937 954 1,000 954 1,052 889 883 969 1,036 1,038 1,034 984 
D
ee
p
-o
rg
a
n
 s
p
a
ce
 S
S
Is
 
Enterobacteriaceae* 10.7% 7.1%  10.2%  11.9% 15.3%  6.4% 13.1%  11.1% 19.1% 22.5% 19.7% 19.5%  20.7%  26.4% 
MRSA† 
 27
.2% 23.7% 31.6% 24.2% 25.1% 27.4% 24.5% 18.9% 14.3%  9.3% 7.2% 4.0% 5.2% 2.9% 
MSSA‡ 
 8
.7% 8.9% 10.2% 15.0%  13.1% 12.4% 11.7%  8.3% 12.9% 9.7% 7.2% 12.9% 12.1% 9.4% 
S. aureus 36.4% 33.0% 41.8% 40.1% 38.9% 41.0% 36.5% 27.2% 27.2% 19.5% 14.8% 16.9%  17.2%  12.3% 
CoNS§ 1.0% 6.3% 8.9%  4.4%  8.4% 5.6% 8.4% 8.8% 10.3%  12.7% 11.7% 12.1% 9.7% 13.0% 
Enterococcus spp. 3.9% 2.7% 0.9% 4.0%  3.3% 5.6% 4.0%  4.1% 5.1% 2.5% 6.1% 5.5% 7.6% 4.7% 
Pseudomonas spp. 2.9%  1.3% 3.1%  4.0%  1.5% 3.4%  2.9% 4.1% 3.7%  3.8% 3.4% 5.5% 4.8%  2.9% 
Other||  45.6% 50.0% 35.1% 36.6% 33.5% 39.2% 35.4% 44.7% 34.6% 39.4% 44.7% 40.4% 40.0%  40.6% 
SSIs with microbiology data 206 224 225 227 275 234 274 217 272 236 264 272 290 276 
Total SSI cases 238 264 263 263 321 280 368 297 334 336 374 390 433 398 
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Table 3: Annual change in the adjusted odds of in-hospital SSIs due to a causative pathogen, pre and post implementation of targeted national 
policies on healthcare associated infections, NHS hospitals, England  
 
  
 
All key pathogens 
 
Staphylococci  
 
Enterobacteriaceae  
 
 
 All key pathogens 
  Trends between 2000 and 2005* Trends between 2005 and 2013*†‡ Trends between 2000 and 2007*† Trends between 2007 and 2013†‡ 
 
 aOR 95% CI P aOR 95% CI P aOR 95% CI P aOR 95% CI P 
All SSIs 
S. aureus 0.98 0.93 – 1.02 0.319 0.86 0.83 – 0.89 <0.001 - - - 0.82 0.78 – 0.86 <0.001 
MRSA 1.01 0.95 – 1.06 0.814 0.71 0.68 – 0.75 <0.001 - - - 0.66 0.62 – 0.72 <0.001 
MSSA 0.94 0.88 – 1.01 0.078 1.06 1.02 – 1.10 0.001 - - - 1.00 0.94 – 1.05 0.930 
Enterobacteriaceae 1.05 0.97 – 1.13 0.214 - - - 1.04 0.99 – 1.09 0.132 1.12 1.07 – 1.18 <0.001 
Total isolates§  n=3,371 n=4,691 n=4,350 n=3,592 
Deep/ 
Organ–space 
SSIs 
S. aureus 1.02 0.94 – 1.11 0.642 0.83 0.79 – 0.88 <0.001 - - - 0.83 0.77 – 0.90 <0.001 
MRSA 0.99 || 0.91 – 1.08 0.894 0.70 0.65 – 0.75 <0.001 - - - 0.66 0.59 – 0.75 <0.001 
MSSA 1.03 || 0.91 – 1.16 0.668 1.04 0.98 – 1.11 0.173 - - - 1.02 0.93 – 1.12 0.647 
CoNS 1.16 || 0.98 – 1.38 0.093 1.07 1.00 – 1.14 0.065 - - - 1.04 0.94 – 1.14 0.455 
Enterobacteriaceae 1.03 || 0.91 – 1.18 0.603 - - - 1.04 || 0.96 – 1.13 0.293 1.14 1.06 – 1.23 0.001 
Total isolates § n=1,005 n=1,854 n=1,348 n=1,502 
CI, Confidence Interval; aOR, adjusted Odds Ratio based on a mixed model adjusting for age, sex, ASA score, duration of operation, wound class, patient days of follow-up, surgical category and variation between 
hospitals; CoNS, coagulase-negative staphylococci; * this period included the ‘Cleanyourhands’ campaign funded by Department of Health rolled out from December 2004 to June 2005; † antimicrobial prescribing 
guidance introduced in late 2007; ‡ this period included inspection of hygiene standards in hospitals by the Healthcare Commission (now the Care Quality Commission) from 2008; § final sample available for analysis 
inclusive of all pathogens in the dataset including those under study; || based on the fixed model due to better fit (lower AIC than the mixed model)   
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Table 4: Changes in the adjusted odds of in-hospital SSI due to S. aureus, MRSA or Enterobacteriaceae by surgical category: pooled data 2008-13 
compared to 2000-05 (baseline), NHS hospitals, England 
 
CI, Confidence Interval; aOR, adjusted Odds Ratio based on a mixed model adjusting for age, sex, ASA score duration of operation, wound class, patient days of follow-up, surgical category (for combined analysis 
only) and variation between hospitals; CABG, coronary artery bypass graft; * model excludes wound class from all three analyses due to underlying sparse data; † results from fixed effects model presented for 
Enterobacteriaceae only due to better model fit (lower AIC); ‡ results from fixed effects model presented for MRSA and S. aureus  due to better model fit (lower AIC); § results from fixed effects model presented for 
all three analyses due to better model fit (lower AIC); || includes SSI cases from gastric surgery although a separate analysis for this category  was not performed  due to low number of SSI cases (n=10 in 2000-05 and 
n=21 in 2008-13); ¶ the data used for the mixed model analysis yields slightly different total SSI cases per pooled period compared to the  sum of cases derived from the eight  individual categories investigated – this is 
because wound class was not included as a covariate in five of eight categories investigated on the basis of sparse data. 
 
 
 
 
 No. SSIs with 
microbiology data 
S. aureus Methicillin-resistant S. aureus (MRSA) Enterobacteriaceae 
 No. (%)  
 
aOR 
 
95% CI 
 
 
P 
No. (%)  
 
aOR 
 
95% CI 
 
 
P 
No. (%)  
 
aOR 
 
 
95% CI 
 
 
P 
  
2000-05 
 
2008-13 
 
2000-05 
 
2008-13 
 
2000-05 
 
2008-13 
 
2000-05 
 
2008-13 
CABG* 355 562 
98 
(27.6%) 
67 
(11.9%) 
0.28 0.17 – 0.44 <0.001 
63 
(17.8%) 
10 
(1.8%) 
0.08 0.04 – 0.19 <0.001 
87 
(24.5%) 
144  
(25.6%) 
1.01 0.69 – 1.48 0.949 
Hip 
hemiarthroplasty*† 
703 521 
420 
(59.7%) 
199 
(38.2%) 
0.41 0.31 – 0.55 <0.001 
304 
(43.2%) 
84 
(16.1%) 
0.23 0.16 – 0.32 <0.001 
40 
(5.7%) 
69 
(13.2%) 
2.45 1.61 – 3.73 <0.001 
Hip prosthesis  749 497 
319 
(42.6%) 
131 
(26.4%) 
0.48 0.36 – 0.64 <0.001 
188 
(25.1%) 
29 
(5.8%) 
0.15 0.09 – 0.24 <0.001 
62 
(8.3%) 
73 
(14.7%) 
1.67 1.12 – 2.50 0.012 
Knee prosthesis *‡ 304 211 
106 
(34.9%) 
46  
(21.8%) 
0.53 0.35 – 0.79 0.002 
50 
(16.5%) 
13 
(6.2%) 
0.34 0.18 – 0.64 0.001 
26 
(8.6%) 
12 
(5.7%) 
0.67 0.32 – 1.43 0.301 
Large bowel 676 792 
163 
(24.1%) 
72 
(9.1%) 
0.26 0.18 – 0.38 <0.001 
133 
(19.7%) 
27 
(3.4%) 
0.14 0.08 – 0.22 <0.001 
104 
(15.4%) 
276 
(34.8%) 
3.13 2.28 – 4.31 <0.001 
Open reduction of 
long bone fracture 
*† 
194 302 
113 
(58.3%) 
118 
(39.1%) 
0.43 0.26 – 0.69 <0.001 
71 
(36.6%) 
42 
(13.9%) 
0.22 0.13 – 0.39 <0.001 
8 
 (4.1%) 
44  
(14.6 %) 
3.89 1.76 – 8.59 0.001 
Small bowel§ 106 109 
28 
(26.4%) 
10 
(9.2%) 
0.28 0.13 – 0.62 0.002 
23 
(21.7%) 
5 
(4.6%) 
0.19 0.07 – 0.52 0.001 
19 
(17.9%) 
36 
(33.0% 
2.28 1.19 – 4.35 0.013 
Vascular* 292 116 
128 
(43.8%) 
30 
(25.9%) 
0.37 0.19 – 0.71 0.003 
91 
(31.2%) 
13 
(11.2%) 
0.24 0.11- 0.52 <0.001 
31 
(10.6%) 
21 
(18.1%) 
2.43 1.10 – 5.39 0.028 
Combined nine 
categories 
(including gastric 
surgery) ||¶ 
3,371 3,126 
1,370 
(40.6%) 
675 
(21.6%) 
0.41 0.36 – 0.47 <0.001 
918 
(27.2%) 
224 
(7.2%) 
0.20 0.17 - 0.24 <0.001 
374 
(11.1%) 
682 
(21.8%) 
2.02 1.72 -2.37 <0.001 
